提示: 手机请竖屏浏览!

慢性阻塞性肺疾病临床特征的最新进展
Update on Clinical Aspects of Chronic Obstructive Pulmonary Disease


Bartolomé R. Celli ... 呼吸系统疾病 • 2019.09.26
相关阅读
• 慢性阻塞性肺疾病患者夜间氧疗的随机试验 • 美泊利单抗治疗嗜酸性粒细胞性慢性阻塞性肺疾病 • COPD患者的单吸入器三联疗法 • 黏液阻塞性肺疾病

慢性阻塞性肺疾病(COPD)是全球第三大死因;2017年,COPD导致320万人死亡,预计这一数字到2040年将达到每年440万人1,2。COPD的全球患病率为10.1%,低收入、中等收入和富裕国家均有许多COPD患者(图1),因COPD而损失的寿命在2007—2017年增加了13.2%1。虽然传统上认为COPD是一种发生于男性的疾病,但某些国家的女性患病率和相关死亡率高于男性。在本综述中,我们介绍了COPD的最新临床进展,重点介绍了COPD的肺部方面,虽然该病也影响其他多个器官系统。在本期发表的另一篇文章3中,Agusti和Hogg讨论了COPD的发病机制,而本刊于不久前发表的一篇关于黏液阻塞性肺疾病的综述4为本文提供了补充。

 

图1. 特定国家19902016年慢性阻塞性肺疾病(COPD)患病率

COPD目前是全球第三大死因,并且是导致并发症的重要原因。虽然COPD在世界各地都是严重问题,但中国和印度的COPD病例占世界总数的50%以上。数据来自《全球疾病负担》(Global Burden of Disease,www.healthdata.org/gbd)。





作者信息

Bartolomé R. Celli, M.D., and Jadwiga A. Wedzicha, M.D.
From the Pulmonary and Critical Care Division, Brigham and Women’s Hospital, and Harvard Medical School — both in Boston (B.R.C.); and the National Heart and Lung Institute, Imperial College London, London (J.A.W.). Address reprint requests to Dr. Celli at 31 River Glen Rd., Wellesley, MA 02481, or at bcelli@copdnet.org.

 

参考文献

1. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1736-1788.

2. Rabe KF, Watz H. Chronic obstructive pulmonary disease. Lancet 2017;389:1931-1940.

3. Agustí A, Hogg JC. Update on the pathogenesis of chronic obstructive pulmonary disease. N Engl J Med 2019;381:1248-1256.

4. Boucher RC. Muco-obstructive lung diseases. N Engl J Med 2019;380:1941-1953.

5. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Am J Respir Crit Care Med 2017;195:557-582.

6. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet 2009;374:733-743.

7. Menezes AM, Hallal PC, Perez-Padilla R, et al. Tuberculosis and airflow obstruction: evidence from the PLATINO study in Latin America. Eur Respir J 2007;30:1180-1185.

8. Celli BR, Agustí A. COPD: time to improve its taxonomy? ERJ Open Res 2018;4(1):00132-2017-00132-2017.

9. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008;32:962-969.

10. Divo MJ, Celli BR, Poblador-Plou B, et al. Chronic obstructive pulmonary disease (COPD) as a disease of early aging: evidence from the EpiChron Cohort. PLoS One 2018;13(2):e0193143-e0193143.

11. Woodruff PG, Couper D, Han MK. Symptoms in smokers with preserved pulmonary function. N Engl J Med 2016;375:896-897.

12. Allinson JP, Hardy R, Donaldson GC, Shaheen SO, Kuh D, Wedzicha JA. The presence of chronic mucus hypersecretion across adult life in relation to chronic obstructive pulmonary disease development. Am J Respir Crit Care Med 2016;193:662-672.

13. Harvey BG, Strulovici-Barel Y, Kaner RJ, et al. Risk of COPD with obstruction in active smokers with normal spirometry and reduced diffusion capacity. Eur Respir J 2015;46:1589-1597.

14. Petersen H, Sood A, Polverino F, et al. The course of lung function in middle-aged heavy smokers: incidence and time to early onset of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2018;198:1449-1451.

15. Rodriguez-Roisin R, Han MK, Vestbo J, Wedzicha JA, Woodruff PG, Martinez FJ. Chronic respiratory symptoms with normal spirometry: a reliable clinical entity? Am J Respir Crit Care Med 2017;195:17-22.

16. Kohansal R, Martinez-Camblor P, Agustí A, Buist AS, Mannino DM, Soriano JB. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham Offspring cohort. Am J Respir Crit Care Med 2009;180:3-10.

17. Gauderman WJ, Urman R, Avol E, et al. Association of improved air quality with lung development in children. N Engl J Med 2015;372:905-913.

18. Morice AH, Celli B, Kesten S, Lystig T, Tashkin D, Decramer M. COPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT). Respir Med 2010;104:1659-1667.

19. Agustí A, Celli B. Avoiding confusion in COPD: from risk factors to phenotypes to measures of disease characterisation. Eur Respir J 2011;38:749-751.

20. Ramírez-Venegas A, Sansores RH, Quintana-Carrillo RH, et al. FEV1 decline in patients with chronic obstructive pulmonary disease associated with biomass exposure. Am J Respir Crit Care Med 2014;190:996-1002.

21. Suzuki M, Makita H, Konno S, et al. Asthma-like features and clinical course of chronic obstructive pulmonary disease: an analysis from the Hokkaido COPD Cohort Study. Am J Respir Crit Care Med 2016;194:1358-1365.

22. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005-1012.

23. Müllerova H, Maselli DJ, Locantore N, et al. Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. Chest 2015;147:999-1007.

24. Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;186:155-161.

25. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet 2007;370:797-799.

26. Bhatt SP, Washko GR, Hoffman EA, et al. Imaging advances in chronic obstructive pulmonary disease: insights from the Genetic Epidemiology of Chronic Obstructive Pulmonary Disease (COPDGene) study. Am J Respir Crit Care Med 2019;199:286-301.

27. Celli BR, Locantore N, Tal-Singer R, et al. Emphysema and extrapulmonary tissue loss in COPD: a multi-organ loss of tissue phenotype. Eur Respir J 2018;51:1-10.

28. de Torres JP, Bastarrika G, Wisnivesky JP, et al. Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. Chest 2007;132:1932-1938.

29. National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume–reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003;348:2059-2073.

30. Criner GJ, Sue R, Wright S, et al. A multicenter randomized controlled trial of Zephyr Endobronchial Valve treatment in heterogeneous emphysema (LIBERATE). Am J Respir Crit Care Med 2018;198:1151-1164.

31. Castaldi PJ, Dy J, Ross J, et al. Cluster analysis in the COPDGene study identifies subtypes of smokers with distinct patterns of airway disease and emphysema. Thorax 2014;69:415-422.

32. Stockley RA, O’Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000;117:1638-1645.

33. Agustí A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012;7(5):e37483-e37483.

34. The National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.

35. Diaz AA, Valim C, Yamashiro T, et al. Airway count and emphysema assessed by chest CT imaging predicts clinical outcome in smokers. Chest 2010;138:880-887.

36. Han MK, Kazerooni EA, Lynch DA, et al. Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology 2011;261:274-282.

37. Washko GR, Hunninghake GM, Fernandez IE, et al. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med 2011;364:897-906.

38. Casanova C, Cote C, de Torres JP, et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:591-597.

39. O’Donnell DE, Laveneziana P. The clinical importance of dynamic lung hyperinflation in COPD. COPD 2006;3:219-232.

40. de-Torres JP, Marín JM, Casanova C, et al. Identification of COPD patients at high risk for lung cancer mortality using the COPD-LUCSS-DLCO. Chest 2016;149:936-942.

41. Spruit MA, Polkey MI, Celli B, et al. Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease. J Am Med Dir Assoc 2012;13:291-297.

42. Puente-Maestu L, Palange P, Casaburi R, et al. Use of exercise testing in the evaluation of interventional efficacy: an official ERS statement. Eur Respir J 2016;47:429-460.

43. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008;372:1107-1119.

44. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31:416-469.

45. Silverman EK, Sandhaus RA. Alpha1-antitrypsin deficiency. N Engl J Med 2009;360:2749-2757.

46. Agusti A, Fabbri LM, Singh D, et al. Inhaled corticosteroids in COPD: friend or foe? Eur Respir J 2018;52:1801219-1801219.

47. Pavord ID, Lettis S, Anzueto A, Barnes N. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. Lancet Respir Med 2016;4:731-741.

48. Zhou Y, Zou Y, Li X, et al. Lung function and incidence of chronic obstructive pulmonary disease after improved cooking fuels and kitchen ventilation: a 9-year prospective cohort study. PLoS Med 2014;11(3):e1001621-e1001621.

49. Casaburi R, ZuWallack R. Pulmonary rehabilitation for management of chronic obstructive pulmonary disease. N Engl J Med 2009;360:1329-1335.

50. Troosters T, Celli B, Lystig T, et al. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur Respir J 2010;36:65-73.

51. Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol–glycopyrronium versus salmeterol–fluticasone for COPD. N Engl J Med 2016;374:2222-2234.

52. Calzetta L, Rogliani P, Matera MG, Cazzola M. A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. Chest 2016;149:1181-1196.

53. Calverley PMA, Anzueto AR, Carter K, et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir Med 2018;6:337-344.

54. Martinez FJ, Vestbo J, Anderson JA, et al. Effect of fluticasone furoate and vilanterol on exacerbations of chronic obstructive pulmonary disease in patients with moderate airflow obstruction. Am J Respir Crit Care Med 2017;195:881-888.

55. Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-789.

56. Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet 2018;391:1076-1084.

57. Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med 2018;378:1671-1680.

58. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365:689-698.

59. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting 60. Rochester CL, Vogiatzis I, Holland AE, et al. An official American Thoracic Society/European Respiratory Society policy statement: enhancing implementation, use, and delivery of pulmonary rehabilitation. Am J Respir Crit Care Med 2015;192:1373-1386.

61. The Long-Term Oxygen Treatment Trial Research Group. A randomized trial of long-term oxygen for COPD with moderate desaturation. N Engl J Med 2016;375:1617-1627.

62. Murphy PB, Rehal S, Arbane G, et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. JAMA 2017;317:2177-2186.

63. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.

64. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000;117:Suppl 2:398S-401S.

65. Wedzicha JA, Calverley PMA, Albert RK, et al. Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J 2017;50:49-49.

66. Celli BR. Dissecting COPD exacerbations: time to rethink our definition. Eur Respir J 2017;50:50-50.

67. Bhatt SP, Wells JM, Iyer AS, et al. Results of a Medicare bundled payments for care improvement initiative for chronic obstructive pulmonary disease readmissions. Ann Am Thorac Soc 2017;14:643-648.

68. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-1138.

69. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006;173:1114-1121.

70. Pinto-Plata VM, Livnat G, Girish M, et al. Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD. Chest 2007;131:37-43.

71. Cote CG, Dordelly LJ, Celli BR. Impact of COPD exacerbations on patient-centered outcomes. Chest 2007;131:696-704.

72. Donaldson GC, Law M, Kowlessar B, et al. Impact of prolonged exacerbation recovery in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015;192:943-950.

73. Criner GJ, Bourbeau J, Diekemper RL, et al. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society guideline. Chest 2015;147:894-942.

74. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999;340:1941-1947.

75. Rochwerg B, Brochard L, Elliott MW, et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. Eur Respir J 2017;50(2):1602426-1602426.

服务条款 | 隐私政策 | 联系我们